

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

TURNOVER FOR THE FIRST QUARTER OF 2023

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce that, the turnover of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2023 (“the First Quarter of 2023”) based on its management accounts which have not been reviewed by the auditors, reached RMB1,191,000,000, representing an increase of 35.6% as compared with the same quarter of 2022, and in particular:

- Turnover of injection products increased by 38.9% to RMB489,000,000;
- Turnover of soft capsule products increased by 21.7% to RMB168,000,000;
- Turnover of granule products increased by 19.8% to RMB145,000,000;
- Turnover of TCM formula granule products increased by 47.7% to RMB325,000,000; and
- Turnover of products in other forms increased by 36.2% to RMB64,000,000.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 41.1%, 14.1%, 12.2% and 27.3% of the total turnover respectively for the First Quarter of 2023.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 8 May 2023

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Liu Tiejun; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Mr. Liu Shun Fai, Mr. Yew Yat On and Ms. Wang Guihua.